The Prevalence of Hyperprolactinemia After Long-term Haloperidol Use in Patients With Chronic Schizophrenia

Jung, Do-Un; Seo, Young-Soo; Park, Jae-hoon; Jeong, Chi-young; Conley, Robert R.; Kelly, Deanna L.; Shim, Joo-Cheol

doi:10.1097/01.jcp.0000186738.84276.9f

Cited by 20 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In studies where rates of prevalence were higher, the dose of haloperidol was also higher [39]. The increase in prolactin levels occurs in a dose dependent manner [6, 28, 40].…”

Section: Resultsmentioning

confidence: 99%

The Effects of Antipsychotics on Prolactin Levels and Women’s Menstruation

Bargiota

Bonotis

Messinis

et al. 2013

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

Introduction. Typical and atypical antipsychotic agent is currently used for treatment in the majority of patients with psychotic disorders. The aim of this review is to assess antipsychotic induced hyperprolactinaemia and the following menstrual dysfunction that affects fertility, quality of life, and therapeutic compliance of women. Method. For this purpose, Medline, PsychInfo, Cochrane library, and Scopus databases were accessed, with a focus on the publication dates between 1954 and 2012. Research of references was also performed and 78 studies were retrieved and used for the needs of this review. Results. A summary of several antipsychotics as well as frequency rates and data on hyperprolactinaemia and menstrual disorders for different agent is presented. Conclusion. Diverse prevalence rates of hyperprolactinaemia and menstrual abnormalities have been found about each medication among different studies. Menstruation plays an important role for women, thus, understanding, careful assessment, and management of hyperprolactinaemia could enhance their lives, especially when dealing with women that suffer from a psychotic disorder.

show abstract

“…In studies where rates of prevalence were higher, the dose of haloperidol was also higher [39]. The increase in prolactin levels occurs in a dose dependent manner [6, 28, 40].…”

Section: Resultsmentioning

confidence: 99%

The Effects of Antipsychotics on Prolactin Levels and Women’s Menstruation

Bargiota

Bonotis

Messinis

et al. 2013

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

show abstract

“…Others have used >10 ng/ml in males and >20 in females [12] and yet others have used >15-16 ng/ml in both sexes [13,14]. The most recent and more conservative reports suggest that >18-20 ng/ml in men and >24 ng/ml in non-pregnant, non-nursing women should be considered the upper limits for prolactin serum concentrations [15-18]. …”

Section: Introductionmentioning

confidence: 99%

“…Our group has been working on identification [18], effective rating [35,57,92], consequences [15,35], recognition [57,68,93] and effective treatment [35,94] of prolactin-associated side effects for over 13 years. We have identified what we think to be the most effective strategy for managing these effects in women and are now running an NIMH funded R01 double blind, placebo controlled randomized clinical trial to address high prolactin levels with associated symptoms in women with schizophrenia, the DAAMSEL study (Dopamine Partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated Prolactin) It is a 4 year study with a target enrollment of 50 women with schizophrenia treated with risperidone, paliperidone or FGAs and with elevated prolactin and sexual side effects (menstrual abnormalities or galactorrhea) at baseline.…”

Section: Introductionmentioning

confidence: 99%

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

et al. 2013

Self Cite

View full text Add to dashboard Cite

Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.

show abstract

“…71 Cohort sizes range from ,50 2 to 2725. 72 In summary for individual antipsychotics, the prevalence is highest in risperidone-treated subjects and amisulpride-treated subjects (72-100%) being significantly higher than patients treated with conventional antipsychotics (33% in a UK cohort on depot antipsychotics). 19 Clinicians have been aware for many years that risperidone is associated with hyperprolactinaemia; however, there has been less clarity whether hyperprolactinaemia is more prevalent than with conventional antipsychotics.…”

Section: Rates Of Hyperprolactinaemia With Individual Antipsychoticsmentioning

confidence: 99%

A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?

Bushe

Bradley

Pendlebury³

2010

Ann Clin Biochem

View full text Add to dashboard Cite

Hyperprolactinaemia is a common adverse event reported in association with treatments used in schizophrenia and bipolar disorder. Recent data are suggestive that hyperprolactinaemia may have a range of significant short-and long-term clinical consequences. The objective of this review is to examine the causes, frequency and clinical consequences of hyperprolactinaemia in the severely mentally ill (SMI) with a focus on patients taking antipsychotic medications. A Medline search was carried out to identify relevant publications. Reference lists from previous review articles were also examined to search for additional data. Hyperprolactinaemia may be one of the most common adverse events associated with some antipsychotic medications. Precise rates with individual drugs had however until recently been poorly categorized. The relationship between hyperprolactinaemia and adverse outcomes in the SMI population appears similar to that in the general population. Adverse outcomes (such as sexual dysfunction) can occur acutely and in the longer term (bone fractures and possibly breast cancer), but the precise link between degree and length of hyperprolactinaemia and adverse outcome remains to be established. In conclusion, hyperprolactinaemia is a common treatment-emergent adverse event of some antipsychotic medications and may have clinical consequences. Physicians must balance the benefits and risks of treatment when determining appropriate therapy for individual patients.

show abstract

The Prevalence of Hyperprolactinemia After Long-term Haloperidol Use in Patients With Chronic Schizophrenia

Cited by 20 publications

References 9 publications

The Effects of Antipsychotics on Prolactin Levels and Women’s Menstruation

The Effects of Antipsychotics on Prolactin Levels and Women’s Menstruation

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?

Contact Info

Product

Resources

About